Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 del Fondo para pymes 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el miércoles 18/06/2025 al final de la jornada laboral. Puede consultar más información aquí.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
190
resultados
Última actualización
21/06/2025 [07:46:00]
Resultados 100 a 125 de 190
Resumen de: AU2023369585A1
The present disclosure relates to RNA molecules encoding a respiratory syncytial virus (RSV). The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the treatment and/or prevention of RSV infection-induced acute respiratory tract illness, including pneumonia and bronchitis.
Resumen de: CN120131653A
本发明公开了谷胱甘肽合成抑制剂和葡萄糖摄取抑制剂的组合、纳米颗粒递送系统及其应用，属于医药领域。本发明证明SLC7A11在肺腺癌中显著过表达，并与不良临床预后相关；通过实验发现谷胱甘肽合成抑制剂和葡萄糖摄取抑制剂的组合在中高SLC7A11表达细胞中表现出增强肺腺癌治疗效果，同时在低表达细胞中也能达到与SLC7A11过表达条件下葡萄糖剥夺相当的效果。为了优化递送方式并最小化全身毒性，本发明还制备了一种双细胞膜包被双药的纳米颗粒递送系统，该系统表现出增强肿瘤靶向和药物可控释放能力，有效解决了肿瘤中SLC7A11表达差异(异质性)问题，并在临床前模型中展示出显著的抗肿瘤效果，为肺腺癌的治疗提供了一种有前景的治疗方法。
Resumen de: CN120131947A
本发明公开了一种多酚包覆的金属氧化物纳米颗粒及其制备方法与应用，所述的纳米颗粒包括掺杂或不掺杂其他金属的金属氧化物内核和多酚类化合物壳层，本发明所述的材料具有作为多种医学影像造影剂的潜力，同时兼具清除活性氧以减少氧化应激的能力，作为诊疗一体化体系的应用潜力较大，此外，本发明的纳米颗粒的制备方法简单，生产成本低等。
Resumen de: FR3156311A1
La présente invention concerne une nanoparticule radioactive de type cœur/enveloppe comprenant : - un cœur à base de silice poreuse comprenant un ou plusieurs radionucléide(s) émetteur(s) α et un ou plusieurs radionucléide(s) émetteur(s) β, et - une enveloppe métallique. La présente invention concerne également l’utilisation de cette nanoparticule radioactive comme médicament, notamment dans la prévention et/ou le traitement du cancer, et/ou comme agent d’imagerie.
Resumen de: CN120131587A
本发明涉及阿霉素脂质体纳米药物的制备方法与应用领域，具体涉及一种地高辛为第五组分的可离子化阿霉素脂质体纳米药物的制备方法及其应用，利用可离子化脂质递送载体在肿瘤组织的酸性微环境作用下的质子化作用(具有叔胺结构的哌嗪在酸性条件下质子化形成阳离子)，与质子化的DOX发生排斥，实现快速、高效释放DOX，降低DOX@D‑LNP的毒副作用；利用具有心血管保护作用的药物DIG降低DOX介导的心脏毒性；同时利用DIG的抗肿瘤作用，提高DOX@D‑LNP的抗肿瘤效果。
Resumen de: CN120131584A
本发明公开了一种纳米药物及其制备方法与应用，涉及生物医药技术领域。本发明的纳米药物包括纳米颗粒和包裹于纳米颗粒中的活性药物；所述纳米颗粒包括载体和修饰于载体表面的靶向肽；所述活性药物为疏水性BCL‑2蛋白抑制剂；所述载体包括甲氧基聚乙二醇聚乳酸‑羟基乙酸共聚物；所述靶向肽包括cRGD肽。本发明的纳米药物基于活化血小板在肿瘤转移中的重要作用，采用cRGD肽修饰的载体靶向递送ABT‑737，特异性诱导活化血小板的凋亡，降低对静息血小板及正常组织的影响，药物的毒副作用降低，显著抑制黑色素瘤肺转移，增强PD‑1抗体的抗转移疗效；本发明的纳米药物基于血小板在多种肿瘤转移中的支持作用，可进一步拓展至黑色素瘤外的其他癌症类型晚期转移的治疗。
Resumen de: US2025186635A1
The present disclosure relates to a plurality of globular nanostructures. Each nanostructure comprises a central part comprising a polymer framework of monomer residues according to {(OR1)(OR2)PO}2—(C){(CH2)mSi(OR3)3}{(CH2)mSi(OR3)3}, wherein each R1 and R2 is independently selected from the group consisting of a negative charge and H; each R3 is independently selected from the group consisting of a negative charge, H and a covalent bond to the polymeric framework; wherein at least 3 R3 are bonds to the polymeric framework; and m is an integer between 1 and 5; and, wherein the central parts of the nanostructures have a volume average hydrodynamic diameter of 10 nm to 90 nm; and an anchoring layer surrounding the central part, wherein the anchoring layer comprises a polymer of monomer residues according to (RO)3Si(CH2)nSi(OR)3, wherein each R is independently selected from the group consisting of a negative charge, H and a covalent bond, wherein at least two R are independently selected from the group consisting of a covalent bond to a monomer residue of the central part and a covalent bond to a monomer residue of the anchoring layer; wherein represents a covalent bond; n is 1 or 2; and wherein the anchoring layer has a thickness of 1-5 nm. The present disclosure also relates to a method for producing such nanostructures as well as the use of the nanostructures and to pharmaceutical compositions comprising such nanostructures.
Resumen de: US2025186402A1
Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.
Resumen de: US2025186387A1
The present disclosure relates to a field of biomedical technology. Embodiments of the present disclosure provide a leonurine nanocomposite hydrogel and preparation method and application thereof, including: dissolving dopamine (DA) monomers and inducing oxidation and self-polymerization of the DA to obtain polydopamine (PDA) nanoparticles, grafting thiol polyethylene glycol folic acid (SH-PEG-FA) on a surface of the PDA nanoparticles to obtain folic acid polydopamine (FA-PDA) nanocarriers; loading a leonurine (Leon) using the FA-PDA nanocarriers of the step 1 to obtain FA-PDA@Leon; encapsulating the FA-PDA@Leon of the step 2 into a gel matrix to obtain gel@FA-PDA@Leon hydrogel.
Resumen de: US2025186361A1
The current invention relates to a method for manufacturing one or more carriers with one or more active pharmaceutical ingredients, wherein said method comprises mixing at least a solution comprising one or more active pharmaceutical ingredients with one or more organic solvents comprising one or more lipids and/or polymers, thereby forming a formulation comprising one or more carriers, and subsequently removing at least part of said one or more organic solvents by a pervaporation step. In a second aspect, said invention also relates to a system for manufacturing such carriers, wherein said system comprises a pervaporation device for removal of one or more organic solvents from a formulation comprising one or more carriers.
Resumen de: AU2025203628A1
The present disclosure relates to RNA particles for delivery of RNA to target tissues after administration, in particular after parenteral administration such as intravenous, intramuscular, subcutaneous or intratumoral administration, and compositions comprising such RNA particles. The RNA particles in one embodiment comprise single-stranded RNA such as mRNA which encodes a peptide or protein of interest, such as a pharmaceutically active peptide or protein. The RNA is taken up by cells of a target tissue and the RNA is translated into the encoded peptide or protein, which may exhibit its physiological activity.
Resumen de: AU2023375897A1
Provided herein are circular RNA constructs comprising an IRES, and at least one expression sequence encoding binding molecule, compositions thereof, and methods of treatment, including for cancer and autoimmune disease. In particular, circular RNA comprising an IRES and a CD19 binder, a HER2 binder, or a BCMA binder are provided, optionally formulated with a delivery vehicle. Precursor polynucleotides comprising an IRES, and at least one expression sequence encoding a CAR construct are also described herein.
Resumen de: US2025186359A1
The present invention features methods for treating, stabilizing, preventing, and/or delaying cancer by administering nanoparticles that comprise rapamycin or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof. The invention further provides combination therapy methods of treating cancer comprising administering to an individual an effective amount of nanoparticles that comprise rapamycin or a derivative thereof and a second therapy.
Resumen de: WO2025121735A1
The present invention relates to a nano-platform comprising core-shell structured upconversion nanoparticles, a composition comprising same, and a treatment method, the nano-platform comprising: a core formed of NaYF4:Yb, Tm through single-step synthesis; and a shell, which encompasses the core and is formed of NaYF4:Nd.
Resumen de: CN119546336A
Disclosed herein are compositions comprising allogeneic, low immunogenic chimeric antigen receptor (CAR)-targeting biomimetic nanovesicles (BioNVs), and methods of treating, preventing, and/or ameliorating cancer using the same.
Resumen de: CN119522092A
The present invention relates to nanoparticles, in particular nanoparticles suitable for delivery of nucleic acids to cells. The nanoparticles comprise multivalent molecules to stabilize nucleic acid molecules in the nanoparticles. In particular, the multivalent molecule has a dendrimer-like structure. The invention also relates to the manufacture of nanoparticles and the use of such nanoparticles in the treatment of disease.
Resumen de: CN119562807A
The present disclosure provides nucleic acid particles comprising an immunomodulator, RNA, and a cationic lipid or cationic polymer, wherein the nucleic acid particles described herein reduce inflammatory responses and/or increase protein or antigen expression associated with a previous formulation.
Resumen de: WO2025118118A1
Carbon monoxide core-shell nanoparticles capable of intravenous administration, a preparation method therefor, and use thereof, belonging to the technical field of nanomedicine. The preparation method for the carbon monoxide core-shell nanoparticles comprises: 1. preparing a polymer carrier PLGA(CO); 2. purifying the PLGA(CO); 3. weighing the PLGA(CO) and a functional material, dissolving them in THF, adding deionized water after ultrasonication, blowing off THF by using nitrogen, carrying out co-precipitation, centrifuging, washing, and carrying out co-precipitation to obtain a nanoparticle functional material @PLGA(CO); and 4. weighing DSPE-PEG, and reacting with the functional material @PLGA(CO) to obtain a functional material @PLGA(CO)@PEG. After a tail intravenous injection, the core-shell structure nanoparticles target a cancer site by means of intravenous injection under the monitoring of NIR-II fluorescence, and CO-enhanced mild temperature photothermal therapy is achieved to eliminate tumors.
Resumen de: WO2025118472A1
Provided is an anti-MET nanobody and an anti-EGFR nanobody, and a bispecific antibody comprising the two nanobodies. Also provided is a drug conjugate constructed on the basis of the nanobodies and the bispecific nanobody.
Resumen de: WO2025119217A1
Provided are a new cationic lipid compound, and a preparation method therefor, a composition thereof and the use thereof. The cationic lipid has a structure as represented by formula I. Lipid nanoparticles prepared from the cationic lipid have a stable nanostructure, have a relatively narrow size distribution, and can be stored for a relatively long time at a low temperature. Moreover, the lipid nanoparticles have relatively good biocompatibility and a relatively high in-vivo mRNA transfection efficiency. The core structures of the cationic lipids can all be constructed by means of a Ugi reaction. The reaction involves simple operation and mild reaction conditions, does not require additional catalysts, has high atomic economy, is simple and easy to carry out, and incorporates inexpensive and readily available raw materials, such that not only is higher safety provided, but the industrial production and quality control of the cationic lipids are also facilitated. The new cationic lipid has good application prospects.
Resumen de: WO2025122871A1
The present disclosure is directed, in some aspects, to oligonucleotide dendrimers comprising a molecular core covalently linked to one or more first oligonucleotide branches, wherein the molecular core is a polyethylene glycol (PEG) core, a polyester (PE) core, or a polyaminoamine (PAMAM) core. The disclosure also provides methods of making and/or using the oligonucleotide dendrimers for, e.g., treating a disease via inducing an immune response.
Resumen de: WO2025121735A1
The present invention relates to a nano-platform comprising core-shell structured upconversion nanoparticles, a composition comprising same, and a treatment method, the nano-platform comprising: a core formed of NaYF4:Yb, Tm through single-step synthesis; and a shell, which encompasses the core and is formed of NaYF4:Nd.
Resumen de: US2025186357A1
The present application relates to ionizable lipids that include ester functional groups. The present application further relates to compositions and uses thereof for the delivery of agents such as nucleic acids and drugs.
Resumen de: WO2025122024A1
The present invention discloses the use of local chemotherapy after laser hyperthermia treatment of a brain tumour. A pharmaceutical composition for local postoperative chemotherapy comprises a chemotherapy drug, in particular doxorubicin, loaded into nanoparticles obtained from a copolymer of amino acids that are natural metabolites in the brain.
Nº publicación: US2025186431A1 12/06/2025
Solicitante:
KYOTO UNIV [JP]
Kyoto University
Resumen de: US2025186431A1
Provided is a pharmaceutical composition for use in radiotherapy, comprising: a compound represented by formula (I) wherein R1 is an aryl group substituted with a substituent selected from an iodine atom and others, wherein the aryl group is optionally substituted with a substituent such as a hydroxy group, X represents a bond or the like and ring A is a group represented by formula (A), wherein R2 is a non-aromatic heterocyclic group optionally substituted with at least one C1-C4 alkyl group, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. Also, provided is a nanoparticle and a method for treating solid cancer using the compound.
BOPI
Sede Electrónica
